Table 1 Gene signatures considered and associated hallmarks of cancer
Signature name | Reference | Number of genes | Associated hallmarks |
|---|---|---|---|
Epithelial mesenchymal transition, MSigDB | MSigDB25 | 200 | Activating invasion and metastasis |
Invasiveness | Marsan et al., 201470 | 16 | Activating invasion and metastasis |
Oxidative phosphorylation, MSigDB | MSigDB25 | 200 | Deregulating cellular energetics |
Reactive oxygen species pathway, MSigDB | MSigDB25 | 49 | Deregulating cellular energetics |
G2M checkpoint, MSigDB | MSigDB25 | 200 | Enabling replicative immortality |
PI3K-AKT-MTor signalling, MSigDB | MSigDB25 | 105 | Evading growth suppressors |
Xenobiotic metabolism, MSigDB | MSigDB25 | 200 | Evading growth suppressors |
DNA repair, MSigDB | MSigDB25 | 150 | Genome instability and mutation, enabling replicative immortality |
p53 Pathway, MSigDB | MSigDB25 | 200 | Genome instability and mutation, enabling replicative immortality |
Hypoxia | Buffa et al.24 | 51 | Inducing angiogenesis |
Angiogenesis, MSigDB | MSigDB25 | 36 | Inducing angiogenesis |
Hypoxia, MSigDB | MSigDB25 | 200 | Inducing angiogenesis |
Angiogenesis, upregulated | Desmedt et al.71 | 5 | Inducing angiogenesis |
Angiogenesis | Masiero et al.69 | 43 | Inducing angiogenesis |
Apoptosis, MSigDB | MSigDB25 | 161 | Enabling replicative immortality |
Apoptosis | Desmedt et al.71 | 4 | Enabling replicative immortality |
Proliferation, upregulated | Desmedt et al.71 | 140 | Sustaining proliferative signalling |
KRAS signalling, up, MSigDB | MSigDB25 | 200 | Sustaining proliferative signalling |
Inflammatory response, MSigDB | MSigDB25 | 200 | Tumour-promoting inflammation, avoiding immune destruction |
IL2-STAT5 signalling, MSigDB | MSigDB25 | 200 | Tumour-promoting inflammation, avoiding immune destruction |
IL6-JAK-STAT3 signalling, MSigDB | MSigDB25 | 87 | Tumour-promoting inflammation, avoiding immune destruction |
TGFβ signalling, MSigDB | MSigDB25 | 54 | Tumour-promoting inflammation, avoiding immune destruction |
TNFα signalling via NF-κB, MSigDB | MSigDB25 | 200 | Tumour-promoting inflammation, avoiding immune destruction |
Immune invasion, upregulated | Desmedt et al.71 | 92 | Tumour-promoting inflammation, avoiding immune destruction |
